[{"id":"da2b0979-fceb-4b41-a878-bc533fb0df47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807126","created_at":"2023-04-11T14:03:25.975Z","updated_at":"2024-07-02T16:35:06.439Z","phase":"Phase 1","brief_title":"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations","source_id_and_acronym":"NCT05807126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3","pipe":" | ","alterations":" HR positive • BRCA mutation • CD47 expression","tags":["IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRCA mutation • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • magrolimab (ONO-7913)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/06/2026","primary_completion_date":" 12/06/2026","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2024-05-02"}]